# Immunogenicity and Safety of Comvigen (Bivalent) Vaccine

> **NCT05930730** · PHASE2 · UNKNOWN · sponsor: **Chulalongkorn University** · enrollment: 450 (estimated)

## Conditions studied

- Safety of a Single Dose of COMVIGEN Vaccine
- Reactogenicity of a Single Dose of COMVIGEN Vaccine
- Immunogenicity of a Single Dose of COMVIGEN Vaccine
- Safety of a Single Dose of BIVALENT Pfizer/BNT Vaccine
- Reactogenicity of a Single Dose of BIVALENT Pfizer/BNT Vaccine
- Immunogenicity of a Single Dose of BIVALENT Pfizer/BNT Vaccine

## Interventions

- **BIOLOGICAL:** Comvigen (Bivalent, ChulaCov19 BNA159.2)
- **BIOLOGICAL:** BIVALENT Pfizer/BNT vaccine

## Key facts

- **NCT ID:** NCT05930730
- **Lead sponsor:** Chulalongkorn University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-09
- **Primary completion:** 2024-02
- **Final completion:** 2024-02
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2023-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05930730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05930730, "Immunogenicity and Safety of Comvigen (Bivalent) Vaccine". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05930730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*